Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 8/20 | 0.66 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.66 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.66 |
| ▸ | CDK2 | P24941 | 4/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.49 |
| ▸ | CDK7 | P50613 | 3/20 | 0.49 |
| ▸ | CCNH | P51946 | 3/20 | 0.49 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | JUN | P05412 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16802771 | 1.00 | MAPK8 (0.66) | MAPK8MAPK9MAPK10CDK2CCNA2 | |
| SCHEMBL16802784 | 0.86 | MAPK8 (0.63) | MAPK8MAPK9MAPK10CDK2CCNA2 | |
| SCHEMBL18148274 | 0.86 | MAPK8 (0.63) | MAPK8MAPK9MAPK10CDK2CCNA2 | |
| SCHEMBL3052427 | 0.84 | MAPK8 (0.60) | MAPK8MAPK9MAPK10CDK2CCNA2 | |
| SCHEMBL16802601 | 0.84 | MAPK8 (0.80) | MAPK8MAPK9MAPK10CDK2CCNA2 | |
| SCHEMBL17910154 | 0.82 | MAPK8 (0.60) | MAPK8MAPK9MAPK10CDK2CCNA2 | |
| SCHEMBL17910138 | 0.81 | MAPK8 (0.56) | MAPK8MAPK9MAPK10CDK2CCNA2 | |
| SCHEMBL10165915 | 0.80 | MAPK8 (0.56) | MAPK8MAPK9MAPK10CDK2MAPK14 | |
| SCHEMBL23003223 | 0.80 | MAPK8 (0.56) | MAPK8MAPK9MAPK10CDK2CCNA2 | |
| SCHEMBL23003226 | 0.80 | MAPK8 (0.56) | MAPK8MAPK9MAPK10CDK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-09-23 | — | — | US | claimed |
| US-20190233418-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-08-01 | — | — | US | claimed |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-03-08 | — | — | US | claimed |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-07-14 | — | — | US | claimed |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMAC, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20190233418-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-08-01 | — | — | US | disclosed |
| US-10294223-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-03-08 | — | — | US | disclosed |
| US-9815834-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9567334-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | MAPK8 1348/4885MAPK9 1181/4885MAPK10 1825/4885 |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | MAPK8 1348/4885MAPK9 1181/4885MAPK10 1825/4885 |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAPK8 1348/4885MAPK9 1181/4885MAPK10 1825/4885 |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | FGFR1, FGFR3, FGFR2 | MAPK8 1422/4885MAPK9 1118/4885MAPK10 1482/4885 |
| US-20190233418-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAPK8 1348/4885MAPK9 1181/4885MAPK10 1825/4885 |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | FGFR1, FGFR3, FGFR2 | MAPK8 1348/4885MAPK9 1181/4885MAPK10 1825/4885 |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | MAPK3, MAP3K3, MAP3K2 | MAPK8 55/4885MAPK9 25/4885MAPK10 31/4885 |
| US-10294223-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | MAPK8 1348/4885MAPK9 1181/4885MAPK10 1825/4885 |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAPK8 1348/4885MAPK9 1181/4885MAPK10 1825/4885 |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAPK8 1348/4885MAPK9 1181/4885MAPK10 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.